Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

New 5-HT4 and/or H3 receptor ligands designed at Synthelabo

Dec. 28, 1998

HSP-117: newly synthesized NK1 receptor antagonist with potent antiemetic effects

Dec. 23, 1998

New series of 5-ht1F agonists disclosed by Lilly

Dec. 23, 1998

Cambridge NeuroScience and Bayer to collaborate on GGF2 development

Dec. 23, 1998

New market launch for novel anticonvulsant: Topamax available in Germany

Dec. 22, 1998

SmithKline Beecham patents combined 5-HT1A/5-HT1B/5-HT1D receptor antagonists

Dec. 22, 1998

Expanded indications, new formulation of Lamictal now available in U.S.

Dec. 21, 1998

First evidence that citicoline favorably affects human brain lipid metabolism

Dec. 21, 1998

EP1 receptor antagonists described by Ono for pain, fever and diuresis

Dec. 21, 1998

Allelix treatment for dementia enters phase I trials

Dec. 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...